General Information of This Drug (ID: DMGJQVI)

Drug Name
GS-6615   DMGJQVI
Synonyms
Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ischemic heart disease DISXQ6WJ BA40-BA6Z Phase 3 [1]
Long QT syndrome DISMKWS3 BC65.0 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8413).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)